ClinicalTrials.gg
CompletedNCT06614153Updated Sep 26, 2024

Pharmacokinetics,Pharmacodynamics,Efficacy and Safety of HRG2010 in Parkinson's Disease Patients With Motor Fluctuations

A Phase 2 interventional study of HRG2010(I) and HRG2010(II) in Parkinson's Disease, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-09-26.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled May 2023, registered Sep 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
61
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 279 studies in Parkinson Disease with a site in China — 128 open to participants now, 135 under way, 3 of them phase 3. Parkinson Disease · China.

Enrollment
72nd of 211
61 · median 47
Started
2023
with 29 others
Phase 2
13 of 279
4 open now
Registered
189th of 279
by date

Among the 279 studies in Parkinson Disease with a site in China, this one is the 72nd largest by enrollment of the 211 interventional ones that give a count, is one of 30 that started in 2023, is one of 13 in phase 2, and was the 189th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

128 of the 279 studies in Parkinson Disease with a site in China are open now. Recruiting first, the newest first:

123 more — sign in →

All 128 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 753 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 279 studies in Parkinson Disease with a site in China, or all of them as a file.
02

Study summary

The study is a multicenter, randomized, open-label, active-controlled, Phase II clinical study. The aim of this trial is to evaluated the pharmacokinetics, pharmacodynamics,efficacy and assessed the safety of HRG2010 compared with a sustained-release cabridopa-levodopa formulation in Parkinson's Disease Patients With Motor Fluctuations.

03

Conditions studied

  • Parkinson's Disease

Browse trials for

04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants diagnosed at age ≥ 40 years with PD, consistent with the International Parkinson and Movement Disorder Society Clinical Diagnostic Criteria and who are being treated with stable regimens of DDCI+LD but experiencing motor fluctuations.
  2. (MMSE) ≥ 25 at Screening Visit.
  3. Hoehn and Yahr Stage II-IV when "on" at Screening Visit.
  4. At Screening, the participant has predictable "Off" periods.
  5. Able and willing to provide a written .

Exclusion criteria

Exclusion Criteria:

  1. Diagnosed with atypical or secondary parkinsonism.
  2. History of narrow angle glaucoma、peptic ulcer disease or upper gastrointestinal hemorrhage.
  3. Had prior functional neurosurgical treatment for PD or if such procedure(s) are planned or anticipated during the study period.
  4. Female who is pregnant, breast-feeding or intends to become pregnant or is of and not using an adequate method.
  5. In the opinion of the clinical investigator, Subjects who should not participate in the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    Group A,Subjects will receive HRG2010(I)

    administered orally

    Drug: HRG2010(I)

  • Experimental
    Group B,Subjects will receive HRG2010(II)

    administered orally

    Drug: HRG2010(II)

  • Active comparator
    Group C,Subjects will receive Sustained-release

    Carbidopa/Levodopa administered orally

    Drug: Sustained-release Carbidopa/Levodopa

Interventions

  • DrugHRG2010(I)

    HRG2010(I)

  • DrugHRG2010(II)

    HRG2010(II)

  • DrugSustained-release Carbidopa/Levodopa

    Sustained-release Carbidopa/Levodopa

06

What researchers measure

Primary outcomes

  1. Change from baseline in average percent "Off" time during waking hours at Day 33

    Time frame: Last three days collected at the end of treatment period

Secondary outcomes

  1. "Off" and"On" time hours during in clinic observation

    Time frame: Days 1 and 13

  2. MDS-UPDRS Part III

    Time frame: Days 1 and 33

  3. Change from baseline in "Off" time at Day 33

    Time frame: Last three days collected at the end of treatment period

  4. Change from baseline in the Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) at Day 33

    Time frame: Day 33

07

Study locations

1 site
  • Beijing Hospital
    Beijing, Beijing 100730, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Jan 2024, 8 months.

Of 97 industry-sponsored phase 2 interventional studies under Parkinson Disease, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 33. This study's 8 months is below that.

Counting every sponsor, half of 202 studies reached it within 28 months; a quarter within 16 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2024
First posted
Sep 26, 2024
StartActual
May 16, 2023
Primary completionActual
Jan 31, 2024
CompletionActual
Mar 4, 2024
Last update
Sep 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06614153
Responsible party
Sponsor
First posted
Sep 26, 2024
Start date
May 16, 2023
Primary completion
Jan 31, 2024
Completion
Mar 4, 2024
Last update
Sep 26, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion